02 Apr 2013, BioSpectrum Bureau , BioSpectrum
Singapore: Certara, leading provider of software and scientific consulting services to improve productivity and decision-making from drug discovery through clinical development, welcomed Mr Hidefumi Kasai to lead the Pacific Rim division of Pharsight Consulting Services.
"The expansion of Pharsight Consulting Services in Japan is a significant milestone in Certara's vision to make Model Based Drug Development more easily available in the Pacific Rim. We are excited to welcome Mr Kasai and believe his experience in PK/PD modeling and simulation, and Model Based Drug Development, will be of significant benefit to our customers," said Mr Hironori Katsuse, Certara's GM for Pacific Rim.
After starting his career at Dainippon Pharmaceutical in 1992, Mr Kasai worked as a research Associate at Clinical PK/PD Research Center, Pharmaceutical Department, School of Medicine, Keio University from 2002, and joined Bellsystem24 (currently spun off into Bell Medical Solutions) in 2006. In addition to having 20 years of experience in population PK/PD and statistical analyses in both nonclinical and clinical drug development, he has contributed to the development of the Model Based Drug Development (MBDD) approach through a variety of related academic societies.
The Pharsight Consulting Services team is the world's largest and most proficient PK/PD consulting group which supports strategic decision-making and regulatory support in drug development. Based in Japan, Mr Kasai will closely collaborate with Certara's global team to engage in modeling of drug candidates by utilizing early clinical study data.